Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 17, Issue 5, 2011, Pages 379-381

  Hicks, C W ^a   Pandya, M M ^b   Itin, I ^b   Fernandez, H H ^b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Dopamine dysregulation; Impulse control disorder; Parkinson's disease; Valproate

Indexed keywords

AMANTADINE; CARBIDOPA; LEVODOPA; PRAMIPEXOLE; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; DEMENTIA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; MALE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; ANTIPARKINSON AGENTS; HUMANS; IMPULSE CONTROL DISORDERS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; VALPROIC ACID;

EID: 79957961827     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.03.003     Document Type: Article

References (10)

1. Voon V., Hassan K., Zurowski M., Duff-Canning S., de Souza M., Fox S., et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006, 66(11):1750-1752.
2. Weintraub D., Siderowf A.D., Potenza M.N., Goveas J., Morales K.H., Duda J.E., et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006, 63(7):969-973.
3. Antonini A., Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease. Incidence, neurobiological basis, management and prevention. Drug Saf 2009, 32(6):475-488.
4. Grant J.E., Potenza M.N. Impulse control disorders. Clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004, 16(1):27-34.
5. Fong T., Kalechstein A., Bernhard B., Rosenthal R., Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 2008, 89(3):298-303.
6. Pallanti S., Quercioli L., Sood E., Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002, 63(7):559-564.
7. Johannessen C.U. Mechanisms of action of valproate: a commentary. Neurochem Int 2000, 37(2-3):103-110.
8. Baf M.H., Subhash M.N., Lakshmana K.M., Rao B.S. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 1994, 24(1):67-72.
9. Yatham L.N. Mood stabilization and the role of antipsychotics. Int Clin Psychopharmacol 2002, 17(Suppl. 3):S21-S27.
10. Armon C., Shin C., Miller P., Carwile S., Brown E., Edinger J.D., et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996, 47(3):626-635.